Pharmacokinetic and Pharmacodynamic Effects of Smoked and Vaporized Cannabis

Cannabis Clinical Trial

Official title:

Pharmacokinetic and Pharmacodynamic Effects of Smoked and Vaporized Cannabis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03676166
• Other study ID #: IRB_00035394
• Status: Completed
• Phase: Phase 1
• Start date: June 16, 2016
• Est. completion date: January 17, 2017

Study information

• Verified date: September 2018
• Source: Johns Hopkins University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Few studies have been conducted to assess the pharmacokinetic and pharmacodynamic effects of smoked and vaporized cannabis. Careful analysis of different cannabis administration methods on these parameters is required to determine the level and duration of biological cannabinoid exposure and associated subjective, cardiovascular and cognitive effects. In the present study the investigators evaluated the detection of cannabinoids in whole blood, oral fluid, and urine, as well as the acute pharmacodynamics associated with smoked and vaporized cannabis among individuals who were not regular cannabis users. The outcomes of the study will extend scientific knowledge about the behavioral pharmacology and toxicology of smoked and vaporized cannabis administration and can inform policies regarding clinical, workplace and roadside drug testing programs.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: January 17, 2017
• Est. primary completion date: January 17, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Have provided written informed consent

2. Be between the ages of 18 and 45

3. Be in good general health based on a physical examination, medical history, vital signs, 12-lead ECG and screening urine and blood tests

4. Test negative for recent cannabis use in urine at the screening visit (confirmed by GC/MS laboratory test) and at clinic admission

5. Test negative for other drugs of abuse, including alcohol at the screening visit and at clinic admission

6. Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission.

7. Have a body mass index (BMI) in the range of 19 to 36 kg/m2

8. Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg

Exclusion Criteria:

1. Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine 3 month prior to the Screening Visit;

2. History of or current evidence of significant medical or psychiatric illness judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.

3. Use of an OTC, systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject.

4. Use of a prescription medication (with the exception of birth control prescriptions) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject.

5. Use of hemp seeds or hemp oil in any form in the past 3 months.

6. Use of dronabinol (Marinol) within the past 6 months.

7. History of xerostomia (dry mouth), or the presence of mucositis, gum infection or bleeding, or other significant oral cavity disease or disorder that in the investigator's opinion may affect the collection of oral fluid samples.

8. History of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina).

9. Abnormal EKG result that in the investigator's opinion is clinically significant.

10. Enrolled in another clinical trial or have received any drug as part of a research study within 30 days prior to dosing.

Related Conditions & MeSH terms

• Cannabis
• Marijuana Abuse

Intervention

Drug:
• Cannabis
Inhaled cannabis

Locations

Country	Name	City	State
United States	Johns Hopkins School of Medicine Behavioral Pharmacology Research Unit	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Johns Hopkins University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Quantity of THC in blood	Quantitative measurement of blood THC by LC-MS/MS	8 hours post exposure
Secondary	Subjective rating of "Drug Effect"	Visual Analog Scale rating of subjective drug effect. Score ranges from 0 (none) to 100 (extreme) using a 100mm line anchored with none/extreme designation.	8 hours post exposure
Secondary	Psychomotor performance as assessed by Digit Symbol Substitution Task	Computerized version of Digit Symbol Substitution Task administered, total correct trials in 90-seconds measured	8 hours post exposure
Secondary	Memory performance as assessed by Paced Auditory Serial Addition Task	Computerized version of Paced Auditory Serial Addition Task administered, total correct trials out of 90 recorded	8 hours post exposure
Secondary	Performance on Divided Attention Task	Computerized Divided Attention Task administered, mean distance from central stimulus and number of targets correct out of 24 recorded	8 hours post exposure